Checkpoint Therapeutics Inc. (CKPT) has secured FDA approval for its lead asset Cosibelimab for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
Cutaneous squamous cell carcinoma, the second most common type of skin cancer in the United States, is estimated to affect around 1.8 million individuals each year, according to the Skin Cancer Foundation. The U.S. cSCC market opportunity is valued at over $1 billion.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.